Home | Business News | Browse by Publication | M | M2 Presswire

"Stocks that Standout" picks for today are: Diagnostic Imaging International Corp.(DIIG) CTS Signs Daytime Coverage Contract!

Article Excerpt
M2 PRESSWIRE-20 April 2009-StandoutStocks.com: "Stocks that Standout" picks for today are: Diagnostic Imaging International Corp.(DIIG) CTS Signs Daytime Coverage Contract!(C)1994-2009 M2 COMMUNICATIONS LTD

RDATE:20042009

StandoutStocks.com "Stocks that Standout" picks for today are: Bionovo, Inc. (NASDAQ: BNVI), Diagnostic Imaging International Corp. (OTCBB: DIIG), Harmonic Inc. (NASDAQ: HLIT), Immunomedics, Inc. (NASDAQ: IMMU), Shutterfly, Inc. (NASDAQ: SFLY)...and Proudly Introducing Proprietary Push Technology (PPT).

The Newest and Revolutionary Technology for Increasing Investor Visability.

REAL Awareness for REAL Companies.

Click below for a full demonstration.

http://newmediaadvisors.info/newmedia.swf

Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at www.Standoutstocks.com

April 20, 2009 -- Bionovo, Inc. (NASDAQ: BNVI) today announced the poster presentation of significant, new data on the nature of the active compound and mechanism of action for its preclinical cancer drug candidate, BN108. The presentation is being made at the 2009 conference of the American Association of Cancer Research (AACR) in Denver, today.

In summary, the study concludes the following:

-- BN108, an aqueous extract of Anemarrhena asphodeloides, selectively induces cell death in breast cancer cells and other tumor cells without having a toxic effect on normal cells.

-- Timosaponin AIII (TAIII) has been identified as an active compound from BN108 that is responsible for the selective activity of BN108 towards breast cancer cells.

-- BN108 and TAIII rapidly and selectively inhibited major pro-survival cellular pathways that are often over-active in breast cancer.

"Currently available treatments for advanced breast cancer patients have limited efficacy and are associated with severe toxicity. Significantly more effective, less toxic therapies are urgently needed. Our studies suggest that therapeutic strategies based on BN108 and TspA3 may achieve more efficacious and safer clinical outcomes for breast cancer patients," stated Emma Shtivelman, Ph.D., the director of cancer research at Bionovo.

"BN108 offers great potential for the treatment of cancer. It is a drug that targets cell survival mechanisms, but it does it only in cancer cells. We anticipate it will have little to no collateral toxicity as is observed with all current cancer chemotherapy," said Isaac Cohen, chairman and CEO of Bionovo, Inc. "Bionovo is looking forward to entering clinical testing with BN108. We believe the market opportunity for drugs that are safe, effective and do not compromise the cancer patient's quality of life is exciting."

Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based...